Immunovant Earnings Estimate

Stocks . USA . 
Stock . Immunovant
IMVT Stock  USD 26.89  0.02  0.07%   
By analyzing Immunovant's earnings estimates, investors can diagnose different trends across Immunovant's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Immunovant is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Immunovant is projected to generate -0.7555 in earnings per share on the 31st of December 2024. Immunovant earnings estimates module stress-tests analyst consensus about projected Immunovant EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Immunovant, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Immunovant's earnings estimates, investors can diagnose different trends across Immunovant's analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to drop to about (242.6 K) in 2024
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Immunovant Earnings per Share Projection vs Actual

About Immunovant Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Immunovant earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Immunovant estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Immunovant fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-825.7 M-784.4 M
Retained Earnings Total Equity-509.7 M-535.2 M
Price Earnings Ratio(16.83)(319,266)
Price Earnings To Growth Ratio(1.69) 3,193 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY